Raymond James Financial
ENTA icon

Raymond James Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Raymond James Financial’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50
Closed -$378 – 5511
2025
Q2 		$378 Buy
+50
New +$301 ﹤0.01% 6704

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial's ENTA Position: Q3 2025 in Review

Raymond James Financial sold out of Enanta Pharmaceuticals (ENTA) in Q3 2025, closing a stake of 50 shares — an estimated $378 sold.

Raymond James Financial first reported a position in ENTA in Q2 2025 and held it in 1 quarter. The position peaked at $378 in Q2 2025. 121 funds tracked by Wall St. Rank hold ENTA as of Q3 2025.

  • Raymond James Financial reported no remaining Enanta Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 50 Enanta Pharmaceuticals shares in Q3 2025, an estimated $378.
  • Raymond James Financial first reported a position in Enanta Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Enanta Pharmaceuticals position peaked at $378 in Q2 2025.
  • 121 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.